Matches in Wikidata for { <http://www.wikidata.org/entity/Q37263260> ?p ?o ?g. }
- Q37263260 description "article científic" @default.
- Q37263260 description "article scientifique" @default.
- Q37263260 description "articolo scientifico" @default.
- Q37263260 description "artigo científico" @default.
- Q37263260 description "artículu científicu espublizáu en 2016" @default.
- Q37263260 description "bilimsel makale" @default.
- Q37263260 description "scientific article published on 17 September 2016" @default.
- Q37263260 description "vedecký článok" @default.
- Q37263260 description "vetenskaplig artikel" @default.
- Q37263260 description "videnskabelig artikel" @default.
- Q37263260 description "vědecký článek" @default.
- Q37263260 description "wetenschappelijk artikel" @default.
- Q37263260 description "wissenschaftlicher Artikel" @default.
- Q37263260 description "наукова стаття, опублікована у вересні 2016" @default.
- Q37263260 description "научни чланак" @default.
- Q37263260 description "مقالة علمية نشرت في 17 سبتمبر 2016" @default.
- Q37263260 name "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results" @default.
- Q37263260 name "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results" @default.
- Q37263260 name "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results." @default.
- Q37263260 type Item @default.
- Q37263260 label "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results" @default.
- Q37263260 label "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results" @default.
- Q37263260 label "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results." @default.
- Q37263260 prefLabel "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results" @default.
- Q37263260 prefLabel "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results" @default.
- Q37263260 prefLabel "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results." @default.
- Q37263260 P1433 Q37263260-52F5AC7C-D49A-47D7-ABCC-EBAF9C41576B @default.
- Q37263260 P1476 Q37263260-1E7EDA27-F2FC-4B61-87A9-5701BC9F94A4 @default.
- Q37263260 P2093 Q37263260-0164FD02-7478-4454-9562-028A0BA7D541 @default.
- Q37263260 P2093 Q37263260-0D080968-FBD8-4CBF-B638-8524E51C987B @default.
- Q37263260 P2093 Q37263260-1912D3D2-21DA-4FC4-BB8C-8B77E10CF782 @default.
- Q37263260 P2093 Q37263260-1E78F52A-59D4-4B23-A78F-32F97AC3979C @default.
- Q37263260 P2093 Q37263260-478BFA8C-AF20-44DF-93A6-7A8D635DFE07 @default.
- Q37263260 P2093 Q37263260-7C913701-1B70-44BC-B76D-6C1F71AD20B2 @default.
- Q37263260 P2093 Q37263260-81A3D571-E2B4-4F4C-96AD-3ED15F3985EE @default.
- Q37263260 P2093 Q37263260-D9E08CD6-A4E9-4A63-8ECF-3EE82B49311A @default.
- Q37263260 P2860 Q37263260-02163A59-3F4D-4695-90A1-1EA8B1E3ED88 @default.
- Q37263260 P2860 Q37263260-10CC54DF-1F8F-4F2C-BB17-ED5EC4E58000 @default.
- Q37263260 P2860 Q37263260-11812B28-F1F3-49A3-B859-769DBD455ECA @default.
- Q37263260 P2860 Q37263260-14112EC3-D346-4738-8FB8-25B3773BE6E4 @default.
- Q37263260 P2860 Q37263260-16E2A7BE-8B74-48EC-A531-62D1EAA6670E @default.
- Q37263260 P2860 Q37263260-16E64327-07F9-4A38-9377-E65900C955C9 @default.
- Q37263260 P2860 Q37263260-1BA5FAC1-31A1-401B-8E2D-4895CC168D59 @default.
- Q37263260 P2860 Q37263260-297B7891-9B98-4687-BF77-B4DFD28EF372 @default.
- Q37263260 P2860 Q37263260-2D58E598-B234-4CED-9AF4-17F7D888437B @default.
- Q37263260 P2860 Q37263260-2F8B5A26-2C85-49CB-8A0F-D23D946C2FE7 @default.
- Q37263260 P2860 Q37263260-3A3A8932-4E17-4558-B08D-F84EF8490831 @default.
- Q37263260 P2860 Q37263260-41192022-0D92-4D07-90B8-9A44D90BF0F1 @default.
- Q37263260 P2860 Q37263260-4D7D5EB5-02FC-4286-996B-5EB85D8D266D @default.
- Q37263260 P2860 Q37263260-4DABF05B-457F-4A8C-BD29-B34918406B29 @default.
- Q37263260 P2860 Q37263260-5672712C-0BBE-46E1-B695-B6F9D2B499D5 @default.
- Q37263260 P2860 Q37263260-5A73C1CB-947C-4D8D-9060-1472D00AA6BD @default.
- Q37263260 P2860 Q37263260-5ADB932A-35DB-4E6B-BFC7-2BA662A3ABC4 @default.
- Q37263260 P2860 Q37263260-64D698A1-B04D-4C1B-B253-F37297CDF14E @default.
- Q37263260 P2860 Q37263260-659C5121-279D-4C6F-B31F-3C9066DA65CD @default.
- Q37263260 P2860 Q37263260-671164FC-E2EC-41C3-9522-546F548D9ADD @default.
- Q37263260 P2860 Q37263260-76F885C9-F508-44D1-B81F-CE627FC8F36C @default.
- Q37263260 P2860 Q37263260-8CA9E5AF-AC6F-434C-8F83-CD02A658CFAE @default.
- Q37263260 P2860 Q37263260-9A24FD3C-97AA-4A9A-8FC2-84882FC31F03 @default.
- Q37263260 P2860 Q37263260-A72D44E3-460F-4EC7-AEF6-5A8000B90696 @default.
- Q37263260 P2860 Q37263260-AE758294-F440-4A8D-A4F7-BE841F31B95B @default.
- Q37263260 P2860 Q37263260-B1BB2C21-1D2E-428D-AC26-71D80D75DE80 @default.
- Q37263260 P2860 Q37263260-B52BA6C1-3645-403F-A857-FE82B0BED69B @default.
- Q37263260 P2860 Q37263260-B5CEACF4-0B16-409F-A591-6DA5930F20F8 @default.
- Q37263260 P2860 Q37263260-BD0BF29B-5F18-4B1C-B5F3-D27F4CED7202 @default.
- Q37263260 P2860 Q37263260-BF63ABB6-8C98-4438-A13F-652EFF650D84 @default.
- Q37263260 P2860 Q37263260-CC78C875-9457-40B1-9738-5731A69F4225 @default.
- Q37263260 P2860 Q37263260-D0840DE9-0F79-484C-8647-37565B5D6D0E @default.
- Q37263260 P2860 Q37263260-DE6345F3-DFCB-4120-8EC5-BEC3DFAE80CD @default.
- Q37263260 P2860 Q37263260-DFCACD84-E1C8-427D-9414-DA906E8FD4E8 @default.
- Q37263260 P2860 Q37263260-E78B5369-7F47-46B3-8855-34D9AD5C6E36 @default.
- Q37263260 P2860 Q37263260-EFD0A210-78C1-40F8-B80B-5B5EAE9C10D7 @default.
- Q37263260 P2860 Q37263260-F4AA5A52-476C-472F-9F38-FA3BC60D6A3D @default.
- Q37263260 P2860 Q37263260-FCFFDDED-CCB9-4530-8380-3C7BE034C948 @default.
- Q37263260 P2860 Q37263260-FE512F50-81B0-4536-9332-B0F94FBAEC02 @default.
- Q37263260 P2888 Q37263260-4C4545D3-7DB4-44AB-8E15-97CE6AAE21D2 @default.
- Q37263260 P304 Q37263260-D3D8CC1B-6770-4C5E-8460-5BF532883714 @default.
- Q37263260 P31 Q37263260-C615D023-B381-4F04-9FE3-FCA102CC82F4 @default.
- Q37263260 P356 Q37263260-B655B554-B477-4882-A38C-56B93AA33D8C @default.
- Q37263260 P433 Q37263260-00FF4D96-EA00-499B-B7A4-AC76681F39C7 @default.
- Q37263260 P478 Q37263260-C694483A-AA99-4F0E-BAE5-385E25E35ADD @default.
- Q37263260 P50 Q37263260-191A40D8-F3F2-458E-89C1-DD0E0C931EF7 @default.
- Q37263260 P50 Q37263260-3E78C294-80C2-4587-887A-C20D1E8E4A34 @default.
- Q37263260 P50 Q37263260-BA8B680E-6120-4704-994D-B52501122B20 @default.
- Q37263260 P50 Q37263260-D4638AD3-F7C2-419D-A656-F37154731DF7 @default.
- Q37263260 P577 Q37263260-1B71B9AB-7FE2-48A7-8913-82DC77256D3D @default.
- Q37263260 P6179 Q37263260-EEC3A26C-B4A1-4031-9790-F3CE3E21695D @default.
- Q37263260 P698 Q37263260-21A1C84D-BA93-4E4E-92D0-AB186AFDD436 @default.
- Q37263260 P921 Q37263260-9F2D5D40-2261-4CA3-8DF2-8947D6CF8504 @default.
- Q37263260 P932 Q37263260-C8F1398B-0BA2-4395-BCDA-A88DEF0D9F13 @default.
- Q37263260 P356 S13014-016-0701-Z @default.
- Q37263260 P698 27639373 @default.
- Q37263260 P1433 Q2313370 @default.
- Q37263260 P1476 "Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results" @default.
- Q37263260 P2093 "Cristina Iftode" @default.
- Q37263260 P2093 "Elisa Villa" @default.
- Q37263260 P2093 "Fiorenza De Rose" @default.
- Q37263260 P2093 "Francesca Lobefalo" @default.
- Q37263260 P2093 "Giuseppe D'Agostino" @default.
- Q37263260 P2093 "Luca Cozzi" @default.